 |
66 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
313 Trials |  |
11771 News |  |
| «12...89101112131415161718...220221» |
- | Journal: Exosomal lncRNA LINC02191 Promotes Laryngeal Squamous cell Carcinoma Progression by Targeting miR-204-5p/RAB22A Axis and Regulating PI3K/Akt/mTOR Pathway. (Pubmed Central) - Oct 21, 2023
Moreover, RAB22A overexpression reversed LINC02191 depletion-triggered suppression of LSCC cell aggressiveness and inactivation of PI3K/Akt/mTOR signaling. In conclusion,
- | Preclinical, Journal: Fibroblast growth factor 21 protects the liver from apoptosis in a type 1 diabetes mouse model via regulating L-lactate homeostasis. (Pubmed Central) - Oct 21, 2023
These results demonstrate that L-lactate homeostasis may be a therapeutic target for T1DM-related hepatic dysfunction. The protective effects of FGF21 on hepatic damage were associated with its ability to ameliorate MCT2-dependent Cori cycle alterations and prevent HCA1-mediated inhibition of ERK1/2, p38 MAPK, and AMPK signaling.
- | Journal: Hydrogen sulfide inhibits gene expression associated with aortic valve degeneration by inducing NRF2-related pro-autophagy effect in human aortic valve interstitial cells. (Pubmed Central) - Oct 20, 2023
In conclusion, HS decreased gene expression levels related to aortic valve degeneration and activated AMPK-mTOR-mediated pro-autophagy function associated with NRF2 in human AVICs. Therefore, HS could be a potential therapeutic target for the development of AS treatment.
- | Preclinical, Journal: Preclinical efficacy of TZG in myofascial pain syndrome by impairing PI3K-RAC2 signaling-mediated neutrophil extracellular traps. (Pubmed Central) - Oct 20, 2023
Experimentally, the expression levels of inducers, biomarkers of NETs formation and vessel injury, and p-PI3K, p-P47, and RAC2 proteins were all significantly up-regulated in affected tissues, which were markedly reversed by TZG. Our results not only shed light into broadening the clinical indications of TZG, but benefit MPS therapy.
- | sirolimus / Generic mfg.
Journal: GDF15 Interference Regulates Proliferation, Inflammation, and Autophagy of Lipopolysaccharide-induced Mesangial Cells by Inhibiting PI3K/ AKT/mTOR Signaling. (Pubmed Central) - Oct 19, 2023
Besides, the expression of NF-?B signaling-, autophagy- (LC3II/I, Beclin l and p62) and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling-related proteins were measured by western blot...Moreover, the PI3K/AKT/ mTOR signal was evidenced to be activated by GDF15 deficiency. The further addition of 740Y-P reversed the impacts of GDF15 deficiency on the proliferation, inflammation, and autophagy of LPS-induced HBZY-1 Collectively, GDF15 downregulation could protect against CGN via blocking PI3K/AKT/mTOR signaling.
- | Journal: Integrin beta1 mediates the effect of telocytes on mesenchymal stem cell proliferation and migration in the treatment of acute lung injury. (Pubmed Central) - Oct 19, 2023
The intraperitoneal injection of TC , TC or MSCs alone, as well as the combination of MSCs with TC or TC exhibited therapeutic effects on LPS-induced acute lung injury. Thus, our data indicate that telocyte ITGB1 contributes to the interaction and intercellular communication between MSCs and TCs, responsible for influencing other cell phenomes and functions.
- | CBT-1 (tetrandrine) / CBA Pharma
Preclinical, Journal: The Neuroprotective Effect of Isotetrandrine on Parkinson's Disease via Anti-Inflammation and Antiapoptosis In Vitro and In Vivo. (Pubmed Central) - Oct 19, 2023
The mRNA level also supported our arguments. The neuroprotection of ITD might be through antineuroinflammation and antiapoptosis pathways via PI3K, ERK, and HO-1.
- Session I: Clinical Studies: Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer: from bench to a phase II clinical trial (Upper Level - Ballroom 6AB - San Diego Convention Center) - Oct 19, 2023 - Abstract #SITC2023SITC_1867;
- || Jakafi (ruxolitinib) / Incyte, parsaclisib (INCB50465) / Incyte
Trial completion date: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) (clinicaltrials.gov) - Oct 18, 2023
P3, N=177, Active, not recruiting, Sponsor: Incyte Corporation
The neuroprotection of ITD might be through antineuroinflammation and antiapoptosis pathways via PI3K, ERK, and HO-1. Trial completion date: Jun 2025 --> Jul 2024
- | Journal: Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway. (Pubmed Central) - Oct 17, 2023
Chloroxine targeted and inhibited the PI3K-AKT-mTOR cascade to repress PCCs growth, migration, as well as invasion, and triggered cellular apoptosis. Therefore, chloroxine may constitute a potential antineoplastic drug for the treatment of pancreatic cancer.
- Management Of Early Relapsed Follicular Lymphoma Debate Favoring Non-Transplant Options () - Oct 17, 2023 - Abstract #EHOC2023EHOC_267;
Treatment with bispecific antibodies, suc as epcoritamab, mosutetuzumab and glofitamab, constitute an alternative to CAR-T...The role of stem cell transplantation in controversial in FL. However, there is not any solid data comparing transplantation with nonchemotherapeutic options.
- | Journal: ROS produced by NOX promote the neurite growth in a PI3K/Akt independent manner. (Pubmed Central) - Oct 16, 2023
Interestingly, the antioxidants increased the p-Akt levels; however, the effect of antioxidants on neurite growth was no dependent on the Akt activity since the inhibitor of PI3K did not modify the antioxidant action on neurite growth. Our results show that the PI3K/Akt pathway participates in neurite growth and that ROS produced by NOX could function as signals in this process; however, this action is not mediated by a redox regulation of Akt activity.
- | Journal: Met stimulates ARID1A degradation and activation of the PI3K-SREBP1 signaling to promote milk fat synthesis in bovine mammary epithelial cells. (Pubmed Central) - Oct 14, 2023
ARID1A gene activation blocked the stimulation of PI3K and SREBP1 mRNA expression by Met. In summary, our data suggests that ARID1A negatively regulates milk fat synthesis stimulated by Met in BMECs through inhibiting the PI3K-SREBP1 signaling pathway, which may provide some new perspectives for improving milk fat synthesis.
- | Halaven (eribulin mesylate) / Eisai
Preclinical, Journal: Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer. (Pubmed Central) - Oct 14, 2023
Mechanistically, we demonstrated that the effect of the combination could be enhanced by inhibiting both the PI3K/AKT and EMT pathways. Therefore, we suggest that paclitaxel resistance is associated with the activation of the PIK3/AKT pathway in PIK3CA-mutated endometrial cancer, and the combination of a PI3K inhibitor and eribulin merits further clinical investigation.
- | LY294002 / Eli Lilly
Journal: Effect of silencing CITED1 gene to regulate PI3K/AKT pathway on the biological function of PTC cells and its mechanism. (Pubmed Central) - Oct 13, 2023
The PI3K and AKT protein levels in the LY294002 group and the siCITED1+LY294002 group were not significantly different (P > 0.05), and were significantly lower than those in the siCITED1 group (P < 0.05). In CITED1 silence may inhibit the progression of PTC cells by inhibiting the PI3K/AKT pathway.
- |||| Aliqopa (copanlisib) / Bayer
Trial primary completion date, Combination therapy: CHRONOS-4: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Oct 12, 2023
P3, N=551, Active, not recruiting, Sponsor: Bayer
In CITED1 silence may inhibit the progression of PTC cells by inhibiting the PI3K/AKT pathway. Trial primary completion date: Mar 2024 --> Sep 2023
- | dactinomycin / Generic mfg.
Journal: Overexpression of FTO inhibits excessive proliferation and promotes the apoptosis of human glomerular mesangial cells by alleviating FOXO6 m6A modification via YTHDF3-dependent mechanisms. (Pubmed Central) - Oct 12, 2023
This study offers insights into the mechanism through which FTO regulates the proliferation and apoptosis of HGMCs by mediating m6A modification of FOXO6 mRNA. These findings also suggest FTO as a potential diagnostic marker and therapeutic target for CGN.
- | Journal, Metabolomic study: Integrated network analysis and metabolomics reveal the molecular mechanism of Yinchen Sini decoction in CCl-induced acute liver injury. (Pubmed Central) - Oct 11, 2023
Combined network analysis and metabolomics showed a link between the key targets (Tlr4, Ptgs2, and Mmp9) and vital metabolites (choline, xanthine, lactate, and 3-hydroxybutyric acid) of YCSND in ALI. Overall, the results contribute to the understanding of the therapeutic effects of YCSND on ALI, and indicate that the integrated network analysis and metabolomics could be a powerful strategy to reveal the pharmacological effects of TCM.
- | Journal: Study on the mechanism of Shenkang injection in the treatment of chronic renal failure based on the strategy of "Network pharmacology-Molecular docking-Key target validation". (Pubmed Central) - Oct 9, 2023
Overall, the results contribute to the understanding of the therapeutic effects of YCSND on ALI, and indicate that the integrated network analysis and metabolomics could be a powerful strategy to reveal the pharmacological effects of TCM. Shenkang injection may inhibit PI3K-Akt signaling pathway to play an anti-chronic renal failure role through the pharmacodynamic component hydroxysafflor yellow A (HSYA), tanshinol, rheum emodin, Astragaloside IV.
- | Imbruvica (ibrutinib) / AbbVie, J&J
Journal: 5-Methoxytryptophan alleviates atrial structural remodeling in ibrutinib-associated atrial fibrillation. (Pubmed Central) - Oct 9, 2023
These findings suggest that 5-MTP administration decreases the vulnerability of ibrutinib-related AF mainly caused by ameliorated maladaptive left atrial remodeling and dysregulation of calcium handling proteins. Mechanistically, 5-MTP treatment markedly enhanced the activation of cardiac PI3K-Akt signaling.
- | Journal: Ultrasound-targeted semaglutide-loaded PEG-nanoliposomes microbubble destruction protects diabetic cardiomyopathy by activating PI3K/Akt/Nrf2 signaling pathway. (Pubmed Central) - Oct 9, 2023
results. UTMD combined Sem-PEG-lips can reduce the oxidative stress of myocardial tissue in DCM rats by activating PI3K/Akt/Nrf2 signaling pathway, thereby improving diabetic myocardial injury.
- | Journal: Influence of METTL3 knockdown on PDLSC osteogenesis in E.?coli LPS-induced inflammation. (Pubmed Central) - Oct 9, 2023
METTL3 knockdown might inhibit osteogenesis in PDLSCs through the inactivation of PI3K/Akt signaling pathway. Concomitant findings might shed novel light on the roles and potential mechanisms of METTL3 in the LPS-stimulated inflammatory microenvironments of PDLSCs.
- ||||| Jakafi (ruxolitinib) / Novartis, Incyte, parsaclisib (INCB50465) / Incyte
Enrollment change, Trial completion date, Trial primary completion date: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) (clinicaltrials.gov) - Oct 6, 2023
P3, N=252, Active, not recruiting, Sponsor: Incyte Corporation
Concomitant findings might shed novel light on the roles and potential mechanisms of METTL3 in the LPS-stimulated inflammatory microenvironments of PDLSCs. N=440 --> 252 | Trial completion date: May 2026 --> Apr 2024 | Trial primary completion date: Nov 2023 --> Aug 2023
- | PX-478 / Seagen
Journal: Respiratory syncytial virus co-opts hypoxia-inducible factor-1?-mediated glycolysis to favor the production of infectious virus. (Pubmed Central) - Oct 5, 2023
in infected cells, which is important for the production of progeny RSV virions. This study contributes to understanding the molecular mechanism by which HIF-1?-mediated glycolysis controls RSV infection and reveals an effective target for the development of highly efficient anti-RSV drugs.
- | pioglitazone / Generic mfg.
Journal: Inhibition of PI3K Signaling Intensified the Antileukemic Effects of Pioglitazone: New Insight into the Application of PPAR? Stimulators in Acute Lymphoblastic Leukemia. (Pubmed Central) - Oct 3, 2023
Taken together, we suggest a novel therapeutic application for PPAR? stimulators as a single agent or in combination with PI3K inhibitors that should be clinically evaluated in ALL patients.
- | Zydelig (idelalisib) / Gilead
Journal, Real-world evidence, IO biomarker, Real-world: Idelalisib (PI3K? inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients. (Pubmed Central) - Oct 3, 2023
Our real-world results suggest that idelalisib is an effective and relatively safe treatment for patients with advanced-stage CLL when no other therapies exist. Alternative dosing regimens and new PI3K inhibitors should be explored, particularly in patients who are double-refractory to inhibitors of BTK and Bcl-2.
- | Journal: PRMT7 Inhibits the Proliferation and Migration of Gastric Cancer Cells by Suppressing the PI3K/AKT Pathway via PTEN. (Pubmed Central) - Oct 2, 2023
Taken together, our findings suggest that PRMT7 can inhibit PI3K/AKT signaling pathway activation by regulating PTEN, thereby inhibiting GC cell proliferation and migration. PRMT7 may be a promising therapeutic target for the prevention of GC.
- | Zolinza (vorinostat) / Merck (MSD)
Journal, PARP Biomarker, IO biomarker: The novel small molecule BH3 mimetic nobiletin synergizes with vorinostat to induce apoptosis and autophagy in small cell lung cancer. (Pubmed Central) - Oct 2, 2023
Furthermore, the combination of nobiletin with vorinostat increased histone H3K9 and H3K27 acetylation levels in SCLC mouse tumor tissue and enhanced the expression of the BH3-only proteins BIM and BID. We conclude that nobiletin is a novel natural BH3 mimetic that can cooperate with vorinostat to induce apoptosis and autophagy in SCLC.
- | Preclinical, Journal: Ugi Adducts as Novel Anti-austerity Agents against PANC-1 Human Pancreatic Cancer Cell Line: A Rapid Synthetic Approach. (Pubmed Central) - Oct 1, 2023
Consequently, Ugi-adduct (R)-11 could be a promising candidate for drug development targeting pancreatic cancer based on the anti-austerity strategy. Our study also demonstrated that the Ugi reaction-based chemical engineering of natural product extracts can be used as a rapid method for discovering novel anti-austerity agents for combating pancreatic cancer.
- Imbruvica (ibrutinib) / AbbVie, J&J
JNK1 inhibitors target distal B-cell receptor signaling overcoming ibrutinib resistance and microenvironmental protection in chronic lymphocytic leukemia (X1) - Sep 30, 2023 - Abstract #DGHO2023DGHO_978;
JNK1 inhibition was even effective in ibrutinib-refractory CLLs in vitro and in vivo and improved the immunosuppressive CLL microenvironment by reducing the frequency of immunosuppressive regulatory T cells (TREGs), while increasing the cytotoxic activity of CD4+ effector T-cells. In conclusion, our study revealed JNK1 inhibition as a promising novel therapeutic option in CLL downstream of the BCR, which can overcome ibrutinib resistance and microenvironmental protection and additionally improves the CLL specific immunosuppression.
- Aliqopa (copanlisib) / Bayer
Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6-year follow-up of CHRONOS-1 (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_454;
The safety profile remained manageable without evidence of late-onset severe toxicities or worsening treatment emergent AEs. To our knowledge, these results constitute the most favorable OS observed to date in patients with iNHL having failed 2 or more prior treatments including an alkylating agent and rituximab.
- | Journal, IO biomarker: Apelin/APJ system protects placental trophoblasts from hypoxia-induced oxidative stress through activating PI3K/Akt signaling pathway in preeclampsia. (Pubmed Central) - Sep 30, 2023
Decrease of placental APJ expression is associated with oxidative stress-induced placental dysfunction in preeclampsia, and increased circulating apelin could be a moderately successful marker to differentiate subjects with preeclampsia from healthy pregnant women. Inhibition of superoxide production and caspase-3 cleavage, together with upregulation of SOD activity/expression and bcl-2/bax ratio, could be the potential molecular mechanisms of apelin-13/APJ protective effects on placental trophoblasts.
- Targeted RNA Expression-Based Signaling Pathway Analysis of Epigenetic Subtypes of Triple Negative Breast Cancers Identifies Mutation-Independent Pathway Activation (255BC, Second Level) - Sep 29, 2023 - Abstract #AMP2023AMP_265;
PI3K mutations are early drivers and lead to distinct DNA methylation signatures; however, they are not associated with increased PI3K pathway activity by RNA expression. In contrast, TNBC without PI3K mutations may show activation of the PI3K pathway in the absence of PI3K/Akt mutations.
- | Journal: NLRP6 potentiates PI3K/AKT signalling by promoting autophagic degradation of p85? to drive tumorigenesis. (Pubmed Central) - Sep 28, 2023
degradation via selective autophagy to drive tumorigenesis, and the interaction between NLRP6 and p85? can be a promising therapeutic target for tumour treatment.
- | LY294002 / Eli Lilly
Preclinical, Journal: Unleashing lactoferrin's antidepressant potential through the PI3K/Akt/mTOR pathway in chronic restraint stress rats. (Pubmed Central) - Sep 28, 2023
Interestingly, LF therapy significantly improved CRS-induced behavioral and biochemical aberrations, an effect which was suppressed upon pretreatment with LY294002 (PI3K inhibitor)...Furthermore, LF succeeded in restoring 5-HT and corticosterone levels, diminishing oxidative stress and ameliorating the inflammatory cascades. Therefore, and for the first time, LF might serve as a promising antidepressant drug through targeting the PI3K/Akt/mTOR pathway.
- | Journal: Myeloid-specific knockout of SHP2 regulates PI3K/PLC? signaling pathway to protect against early myocardial infarction injury. (Pubmed Central) - Sep 28, 2023
Myeloid-specific knockout of SHP2 regulates PI3K/PLC? signaling pathway to protect against early myocardial infarction injury.
- | Journal: Theabrownin from Dark Tea Ameliorates Insulin Resistance via Attenuating Oxidative Stress and Modulating IRS-1/PI3K/Akt Pathway in HepG2 Cells. (Pubmed Central) - Sep 28, 2023
Treatment with the PI3K inhibitor demonstrated a favorable correlation between PI3K activation and TB action on glycolipid metabolism. Notably, we observed that TB2 had a greater effect on improving insulin resistance compared with TB1, which, due to its prolonged fermentation time, increased the degree of oxidative polymerization of TB.
- | LY294002 / Eli Lilly, PD98059 / Wayne State University
Preclinical, Journal: Cerebroprotective Effect of 17?-Estradiol Replacement Therapy in Ovariectomy-Induced Post-Menopausal Rats Subjected to Ischemic Stroke: Role of MAPK/ERK1/2 Pathway and PI3K-Independent Akt Activation. (Pubmed Central) - Sep 28, 2023
Thus, these results suggested that E2 pretreatment in ovariectomized female rats modulates MAPK/ERK1/2 and activates Akt independently of PI3K to promote cerebroprotection in ischemic stroke. A better understanding of the mechanisms and the influence of E2 in the female sex paves the way for the design of future successful hormone replacement therapies.
- | Journal: Piperine Induces Apoptosis and Autophagy in HSC-3 Human Oral Cancer Cells by Regulating PI3K Signaling Pathway. (Pubmed Central) - Sep 28, 2023
We also confirmed that piperine inhibits oral cancer tumor growth in vivo via antitumor effects related to apoptosis and PI3K signaling pathway inhibition. Therefore, we suggest that piperine can be considered a natural anticancer agent for human oral cancer.
- | tamoxifen / Generic mfg.
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy. (Pubmed Central) - Sep 28, 2023
NET influences the composition and functional state of the infiltrating immune cells. Furthermore, changes in the immune microenvironment are also associated with treatment response.
- || Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Review, Journal, IO biomarker: Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach. (Pubmed Central) - Sep 28, 2023
Targeted therapies represent a paradigm shift in the treatment of FL. Further studies are needed to directly compare these targeted therapies and their combinations, as well as to investigate biomarkers predictive of response.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Upregulation of metabolism enzymes mediatesADC resistance in a HER2-positive cancer cell line (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1464;
Conclusions In this study, we established an Enhertu resistant N87 cell line and investigated the mechanism of drug resistance. Our results showed increased expression of HER2 downstream signals containing PI3K-AKT signal and MAPK signal lead to resistance of N87-R cells and inhibition of PI3K signal or MAPK signal reversed the resistance of tumor cells both in vitro and in vivo.
- PIK3IP1/TrIP immune regulation on CD8+ T cells restricts anti-tumor immunity (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1334;
Our results showed increased expression of HER2 downstream signals containing PI3K-AKT signal and MAPK signal lead to resistance of N87-R cells and inhibition of PI3K signal or MAPK signal reversed the resistance of tumor cells both in vitro and in vivo. Our affinity stimulation studies suggest TrIP
- | Journal: Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach. (Pubmed Central) - Sep 26, 2023
Therefore, the present study identifies new molecules and provides evidence for salvianolic acid A for dual inhibition. Further experiments must be performed both in vitro and in vivo to support the predictions of these computational tools.
- | LY294002 / Eli Lilly
Journal: Osteopontin promotes gastric cancer progression via phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway. (Pubmed Central) - Sep 25, 2023
These results suggested that OPN though PI3K/AKT/mammalian target of rapamycin signal pathway to up-regulate MMP-2 and VEGF expression, which contribute SGC-7901 cells to proliferation, invasion and migration. Thus, our results demonstrate that OPN may serve as a novel prognostic biomarkers as well as a potential therapeutic targets for GC.
- | Journal: Sanguisorba officinalis ethyl acetate extract attenuates ulcerative colitis through inhibiting PI3K-AKT/NF-?B/ STAT3 pathway uncovered by single-cell RNA sequencing. (Pubmed Central) - Sep 25, 2023
Thus, our results demonstrate that OPN may serve as a novel prognostic biomarkers as well as a potential therapeutic targets for GC. By integrating the chemical information of SOEA derived from UPLC-Q-Orbitrap-HRMS with single-cell transcriptomic data extracted from scRNA-seq, this study demonstrates that SOEA exerts the therapeutic effect through suppressing PI3K-AKT/NF-B/STAT3 pathway to improve clinical symptoms, inflammatory response, mucosal barrier, and intercellular interactions in UC, and effectively eliminates the interference of cellular heterogeneity.
- | Journal, IO biomarker: Silencing POLE2 promotes apoptosis and inhibits proliferation of oral squamous cell carcinomas by inhibiting PI3K/AKT signaling pathway. (Pubmed Central) - Sep 25, 2023
In addition, POLE2 regulates OSCC progression by inhibiting the PI3K/AKT pathway. POLE2 is closely related to the progression of OSCC, and POLE2 may be a potential target for OSCC treatment.
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Erleada (apalutamide) / J&J, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Observational data, Retrospective data, Review, Clinical Trial,Phase II, Journal, Checkpoint inhibition: Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review. (Pubmed Central) - Sep 25, 2023
Case 2 was diagnosed with PI3Ki-related diabetes mellitus, and her blood glucose level returned to normal with the use of metformin and dapagliflozin. We systematically searched the PubMed database for articles on ICI- and PI3Ki-related diabetes mellitus and characterized the differences in clinical features and treatment between these two forms of diabetes.
- | Preclinical, Journal, IO biomarker: Parthenolide repressed endometriosis induced surgically in rats: Role of PTEN/PI3Kinase/AKT/GSK-3?/?-catenin signaling in inhibition of epithelial mesenchymal transition. (Pubmed Central) - Sep 25, 2023
Our findings showed that parthenolide in a dose dependent manner inhibited PI3K/AKT/GSK-3?/n?-catenin cascade via enhancement of PTEN with subsequent inhibition of EMT evidenced by elevation of the epithelial marker, E-cadherin and reduction of mesenchymal marker, vimentin, of the endometriotic implants in addition to reversal of invasion and migration properties of epithelial endometriotic cell lines. These findings provide a valuable therapeutic approach for treatment of endometriosis.
- | GLG-302 / GLG Pharma
Preclinical, Journal: Ciliary neurotrophic factor stimulates stem/progenitor Leydig cell proliferation but inhibits differentiation into its lineage in rats. (Pubmed Central) - Sep 25, 2023
These findings provide a valuable therapeutic approach for treatment of endometriosis. Ciliary neurotrophic factor stimulates proliferation but blocks the differentiation of stem/progenitor Leydig cells.